---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-24-000165"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:35:48.309476+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q4 revenue $902M (+9%); FY24 guides $3.93-4.04B, EPS $10.84-11.33

## Summary
- Q4 revenue $902M, up 9% reported and 8% organic; CAG Diagnostics recurring revenue +11% reported and +10% organic.
- Q4 EPS $2.32, up 13% reported and 17% on a comparable basis; full-year EPS $10.06 (+25% reported).
- FY24 revenue guidance $3.93B-$4.04B (+7.5%-10.5% reported); EPS $10.84-$11.33 (+8%-13% comparable).
- Full-year operating margin expanded 330 bps reported; FY24 operating margin target 30.2%-30.7%.
- New IDEXX inVue Dx slide-free cellular analyzer launch targeted for late 2024.

## SEC filing metadata
- accession: 0001157523-24-000165
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000115752324000165/0001157523-24-000165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000115752324000165/a53891750.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-24-000165
- JSON: https://secwatch.observer/filing/0001157523-24-000165.json
- Plain text: https://secwatch.observer/filing/0001157523-24-000165.txt

## Key facts
- Earnings Releases
  IDEXX LABORATORIES INC /DE updated its the quarter and year ended December 31, 2023 guidance (initiated).
  - Period: the quarter and year ended December 31, 2023
  - Guidance: initiated
  - Result: reported results
  source text: IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/874716/000115752324000165/0001157523-24-000165-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.